Results 101 to 110 of about 3,957,184 (313)

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Factors that influence patient preferences for prostate cancer management options: a systematic review

, 2015
Timothy N Showalter,1 Mark V Mishra,2 John FP Bridges31Department of Radiation Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA; 2Department of Radiation Oncology, University of Maryland School of Medicine, 3Department of ...
Showalter TN, Mishra MV, Bridges JFP
core  

Patient perceptions and preferences of minimally invasive treatment modalities in varicose veins: a cross-sectional survey

Frontiers in Cardiovascular Medicine
PurposeMinimally invasive therapies (MIT) have gained popularity due to their capacity to reduce trauma, enhance aesthetic outcomes, and shorten recovery periods.
Qian Li, Xiaotao Wang, Bin Meng, Xinle Chen, Mingmin Xu   +4 more
doaj   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Patient preferences for antiretroviral therapy: effectiveness, quality of life, access and novel delivery methods

, 2017
Ellen F Eaton,1 Chastity McDavid,1 Mary Katy Banasiewicz,1 Michael J Mugavero,1 Sara J Knight2 1Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; 2Division of Preventive Medicine ...
Eaton EF, Knight SJ, McDavid C, Mugavero MJ, Banasiewicz MK   +4 more
core  

Understanding Patient Preferences Regarding the Important Determinants of Breast Cancer Treatment: A Narrative Scoping Review

, 2023
Hui Yee Yeo,1,2 Ai Ch’i Liew,2 Suz Jack Chan,1 Mudassir Anwar,1 Catherine Hye-Won Han,3 Carlo A Marra1 1School of Pharmacy, University of Otago, Dunedin, New Zealand; 2Clinical Research Center, Hospital Seberang Jaya, Penang, Malaysia; 3Faculty of ...
Han CHW, Marra CA, Chan SJ, Anwar M, Yeo HY, Liew AC   +5 more
core  

Patient priorities in coordinated care: a literature review to identify patients' preferences

International Journal of Integrated Care, 2009
Alexander Mühlbacher, Susanne Bethge
doaj   +3 more sources

Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer

Molecular Oncology, EarlyView.
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani, Dominic Guanzon, Andrew Lai, Katherin Scholz‐Romero, Sarah Reed, Edita Ritmejeryte, Rohan Lourie, Naven Chetty, Kaltin Ferguson, Carlos Salomon   +9 more
wiley   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira, Ana Teixeira‐Marques, Rui Freitas, João A Carvalho, Sara Monteiro‐Reis, Giorgio I. Russo, Rui Henrique, Carmen Jerónimo   +7 more
wiley   +1 more source

Assessing patient preferences in heart failure using conjoint methodology

, 2015
Giovanni Pisa,1 Florian Eichmann,1 Stephan Hupfer21Kantar Health GmbH, Munich, Germany; 2Novartis Pharma GmbH, Nuernberg, GermanyAim: The course of heart failure (HF) is characterized by frequent hospitalizations, a high mortality rate, as well as a ...
Eichmann F, Hupfer S, Pisa G
core